Madison Square Garden Sports Co (MSGS) Stock Price & How to Invest

Madison Square Garden Sports Corp. owns and operates the New York Knickerbockers of the NBA and the New York Rangers of the NHL, along with two development-league affiliates and a professional sports team performance business. Its revenue comes from ticket sales and premium seating, local media rights fees, sponsorship and signage, food and merchandise at games, and its share of leaguewide national media and licensing money. The company does not own Madison Square Garden itself: the arena sits inside MSG Entertainment, and the Knicks and Rangers pay to play there under long-term arrangements, which is why the reported financials look thinner than the size of the underlying assets suggests. Revenue for the trailing twelve months through June 2026 is roughly ~$1.15 billion against a market capitalization of about ~$9.6 billion, a ratio that only makes sense once you treat the company as an asset holder rather than an operating business.

The investment picture is dominated by the spread between accounting results and franchise value. Sportico's most recent valuations put the Knicks around ~$9.85 billion (third in the NBA) and the Rangers around ~$3.65 billion (second in the NHL), for a combined figure near ~$13.5 billion, while the equity trades at roughly ~$9.6 billion and the company earned only ~$8 million of GAAP net income over the twelve months to June 2026. Historically that discount was explained by the control structure, the absence of a dividend, and the fact that no minority holder can force a sale of a team. In February 2026 the board approved exploration of a tax-free separation of the Knicks business from the Rangers business, and a confidential Form 10 was filed with the SEC in May 2026, the process that pulled the stock up roughly 82% over the past year (and ~53% in 2026) to about ~$397 a share as of October 16, 2026. On September 30, 2026 the board approved the spin-off of the Rangers: holders of record on October 20, 2026 receive one share of MSG Rangers Corp. for every two MSG Sports shares, distributed on October 26, with MSG Rangers Class A trading on the NYSE as MSGR from October 27 (when-issued as MSGR WI from October 21). The remaining company, which keeps the Knicks, is renamed MSG Knickerbockers Corp. and its Class A stock trades as MSGK. What is being priced now is the assets themselves, split into two cleaner wrappers, rather than the probability that the structure changes.

The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. The spin-off has been approved and scheduled, so the main uncertainty has moved from whether it happens to how the two pieces trade: the Rangers company in particular will be a smaller, thinner stock, and nothing in the separation changes Dolan control of either. The company generates little in the way of reported profit (trailing twelve-month net income of only ~$8 million on ~$1.15 billion of revenue as of June 2026, after a ~$22 million loss in fiscal 2025), so there is no earnings support underneath the price if franchise appraisals stop rising. Player compensation, collective bargaining outcomes and luxury-tax structures in both leagues can raise costs faster than revenue, and local media rights remain the softest part of the model. Debt of ~$1.16 billion sits against ~$165 million of cash, and how it is divided between the two companies matters to each one's equity value. Finally, with roughly ~24 million shares outstanding, the float is small and the stock can move sharply on transaction headlines in either direction.

5 analysts publish price targets on MSGS, averaging $493.80 against a $384.39 price as of November 2026, or +28.5%. The published targets run from $450.00 to $584.00, a narrow spread, and the ratings split 5 buy, 2 hold, 0 sell. Over the last six months there have been 11 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MSGS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Madison Square Garden Sports Co. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Franchise scarcity. There are 30 NBA teams and 32 NHL teams, and the two in the largest US media market almost never change hands. The most optimistic published target, $584.00, assumes this works close to its best case.

The case against. The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. The most pessimistic target, $450.00, is roughly what MSGS is worth if this bites instead.

Read the full bull and bear case on MSGS, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Madison Square Garden Sports Co (MSGS) has had one share split in the last 10 years:

• 1402:1000 on April 20, 2020, so every share held became 1.402 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of MSGS the day before the 1402:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Madison Square Garden Sports Co's investor relations page or your broker.

• Share price: ~$397 (October 16, 2026)
• Market capitalization: ~$9.6 billion
• Revenue (TTM, through June 2026): ~$1.15 billion
• Net income (TTM): ~$8 million (EPS ~$0.32)
• Franchise value estimate: ~$13.5 billion combined (Knicks ~$9.85B, Rangers ~$3.65B per Sportico)
• Debt / cash: ~$1.16 billion / ~$165 million
• Spin-off terms: 1 MSG Rangers (MSGR) share per 2 MSGS shares; record Oct 20, distribution Oct 26, 2026

Conventional earnings multiples do not describe this stock: on ~$8 million of trailing net income the trailing P/E is above 1,000x, and forward EPS is negative because the September quarter is the off-season. The more common framework is a sum-of-the-parts, comparing the market capitalization of about ~$9.6 billion against combined franchise appraisals near ~$13.5 billion and then adjusting for ~$1.16 billion of debt and for the discount attached to a controlled structure. That gap narrowed as the shares rose ~82% over the past year off a 52-week low near ~$208, and from October 27, 2026 the market will price the Knicks (MSGK) and Rangers (MSGR) separately.

If you want MSGS exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to MSGS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MSGS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (IJT, SLYG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so MSGS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MSGS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MSGS is a franchise-value asset wrapped in a controlled corporate structure, and the whole debate is how much of that private-market value a minority public holder can actually reach. From October 27, 2026 that debate splits into two stocks, MSGK for the Knicks and MSGR for the Rangers, each still controlled by the Dolan family.

Whether MSGS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MSGS a buy or a sell?, and where the stock could go from here in the MSGS stock forecast.

For income investors, whether MSGS pays a dividend and how the payout looks is covered in does MSGS pay a dividend? And to weigh MSGS against a peer, read the full side-by-side comparisons: MSGS vs BATRA and MSGS vs BATRK.